Nomura Asset Management Co. Ltd. Purchases 26,680 Shares of Stryker Corporation $SYK

Nomura Asset Management Co. Ltd. boosted its holdings in Stryker Corporation (NYSE:SYK) by 16.3% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 190,135 shares of the medical technology company’s stock after buying an additional 26,680 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Stryker were worth $75,223,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares in the last quarter. Edgestream Partners L.P. boosted its position in shares of Stryker by 27.0% during the first quarter. Edgestream Partners L.P. now owns 893 shares of the medical technology company’s stock worth $332,000 after acquiring an additional 190 shares during the last quarter. Diversify Advisory Services LLC purchased a new position in Stryker during the first quarter valued at $200,000. Private Advisor Group LLC increased its holdings in Stryker by 6.7% in the 1st quarter. Private Advisor Group LLC now owns 17,100 shares of the medical technology company’s stock valued at $6,366,000 after acquiring an additional 1,073 shares during the last quarter. Finally, Kestra Private Wealth Services LLC lifted its stake in Stryker by 2.2% in the 1st quarter. Kestra Private Wealth Services LLC now owns 19,476 shares of the medical technology company’s stock worth $7,250,000 after purchasing an additional 412 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $410.00 target price on shares of Stryker in a report on Friday. Redburn Partners set a $420.00 price objective on Stryker in a research note on Thursday, September 18th. Truist Financial upped their price objective on Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a report on Friday. Evercore ISI cut their target price on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Finally, Wells Fargo & Company upped their price target on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday. Thirteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $434.37.

Insider Activity

In other Stryker news, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 520,500 shares of company stock worth $184,803,065 over the last quarter. 5.90% of the stock is currently owned by insiders.

Stryker Stock Performance

NYSE SYK opened at $362.39 on Monday. The business’s 50 day moving average price is $371.96 and its 200-day moving average price is $381.27. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a market cap of $138.59 billion, a P/E ratio of 48.00, a P/E/G ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same period in the previous year, the firm earned $2.87 earnings per share. Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.